Biogen, Inc. (BIIB)
220.83
-3.68
(-1.64%)
USD |
NASDAQ |
Sep 04, 16:00
220.90
+0.06
(+0.03%)
After-Hours: 20:00
Biogen Research and Development Expense (Quarterly) : 461.70M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 461.70M |
| March 31, 2026 | 471.10M |
| December 31, 2025 | 434.00M |
| September 30, 2025 | 369.60M |
| June 30, 2025 | 332.10M |
| March 31, 2025 | 362.70M |
| December 31, 2024 | 459.50M |
| September 30, 2024 | 470.00M |
| June 30, 2024 | 442.00M |
| March 31, 2024 | 383.60M |
| December 31, 2023 | 507.40M |
| September 30, 2023 | 672.20M |
| June 30, 2023 | 519.70M |
| March 31, 2023 | 508.50M |
| December 31, 2022 | 536.90M |
| September 30, 2022 | 485.00M |
| June 30, 2022 | 461.40M |
| March 31, 2022 | 475.40M |
| December 31, 2021 | 632.90M |
| September 30, 2021 | 637.30M |
| June 30, 2021 | 530.40M |
| March 31, 2021 | 465.40M |
| December 31, 2020 | 1.675B |
| September 30, 2020 | 1.089B |
| June 30, 2020 | 596.30M |
| Date | Value |
|---|---|
| March 31, 2020 | 427.90M |
| December 31, 2019 | 646.50M |
| September 30, 2019 | 540.40M |
| June 30, 2019 | 484.80M |
| March 31, 2019 | 563.70M |
| December 31, 2018 | 611.60M |
| September 30, 2018 | 507.90M |
| June 30, 2018 | 981.00M |
| March 31, 2018 | 496.70M |
| December 31, 2017 | 587.60M |
| September 30, 2017 | 446.40M |
| June 30, 2017 | 796.20M |
| March 31, 2017 | 423.40M |
| December 31, 2016 | 533.90M |
| September 30, 2016 | 529.00M |
| June 30, 2016 | 473.10M |
| March 31, 2016 | 437.30M |
| December 31, 2015 | 541.70M |
| September 30, 2015 | 519.86M |
| June 30, 2015 | 490.73M |
| March 31, 2015 | 460.55M |
| December 31, 2014 | 500.09M |
| September 30, 2014 | 417.17M |
| June 30, 2014 | 447.27M |
| March 31, 2014 | 528.88M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | 216.41M |
| AbbVie, Inc. | 2.344B |
| Regeneron Pharmaceuticals, Inc. | 1.508B |
| Vertex Pharmaceuticals, Inc. | 993.80M |
| Amgen, Inc. | 1.868B |